SG10201801658XA - Methods and compositions for rna-guided treatment of hiv infection - Google Patents
Methods and compositions for rna-guided treatment of hiv infectionInfo
- Publication number
- SG10201801658XA SG10201801658XA SG10201801658XA SG10201801658XA SG10201801658XA SG 10201801658X A SG10201801658X A SG 10201801658XA SG 10201801658X A SG10201801658X A SG 10201801658XA SG 10201801658X A SG10201801658X A SG 10201801658XA SG 10201801658X A SG10201801658X A SG 10201801658XA
- Authority
- SG
- Singapore
- Prior art keywords
- rna
- compositions
- methods
- hiv infection
- guided treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16061—Methods of inactivation or attenuation
- C12N2740/16063—Methods of inactivation or attenuation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Developmental Biology & Embryology (AREA)
- Tropical Medicine & Parasitology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361871626P | 2013-08-29 | 2013-08-29 | |
US201462018441P | 2014-06-27 | 2014-06-27 | |
US201462026103P | 2014-07-18 | 2014-07-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201801658XA true SG10201801658XA (en) | 2018-03-28 |
Family
ID=52587370
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201801658XA SG10201801658XA (en) | 2013-08-29 | 2014-08-29 | Methods and compositions for rna-guided treatment of hiv infection |
SG11201601313TA SG11201601313TA (en) | 2013-08-29 | 2014-08-29 | Methods and compositions for rna-guided treatment of hiv infection |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201601313TA SG11201601313TA (en) | 2013-08-29 | 2014-08-29 | Methods and compositions for rna-guided treatment of hiv infection |
Country Status (15)
Country | Link |
---|---|
US (24) | US9925248B2 (en) |
EP (1) | EP3038661B1 (en) |
JP (3) | JP7118588B2 (en) |
KR (2) | KR20230017364A (en) |
CN (1) | CN106102781A (en) |
AU (2) | AU2014312123A1 (en) |
BR (1) | BR112016004091A2 (en) |
CA (1) | CA2922428A1 (en) |
CL (1) | CL2016000424A1 (en) |
EA (1) | EA037850B1 (en) |
IL (1) | IL244220B (en) |
MX (1) | MX2016002586A (en) |
SG (2) | SG10201801658XA (en) |
WO (1) | WO2015031775A1 (en) |
ZA (1) | ZA201601344B (en) |
Families Citing this family (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2012333134B2 (en) | 2011-07-22 | 2017-05-25 | John Paul Guilinger | Evaluation and improvement of nuclease cleavage specificity |
IL293526A (en) | 2012-12-12 | 2022-08-01 | Harvard College | C delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications |
EP3434776A1 (en) | 2012-12-12 | 2019-01-30 | The Broad Institute, Inc. | Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof |
CN104995302B (en) | 2013-01-16 | 2021-08-31 | 爱默蕾大学 | CAS 9-nucleic acid complexes and uses related thereto |
US10760064B2 (en) | 2013-03-15 | 2020-09-01 | The General Hospital Corporation | RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci |
KR102405549B1 (en) | 2013-03-15 | 2022-06-08 | 더 제너럴 하스피탈 코포레이션 | Using truncated guide rnas (tru-grnas) to increase specificity for rna-guided genome editing |
CA2908697C (en) | 2013-04-16 | 2023-12-12 | Regeneron Pharmaceuticals, Inc. | Targeted modification of rat genome |
AU2014281031B2 (en) | 2013-06-17 | 2020-05-21 | Massachusetts Institute Of Technology | Delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions for targeting disorders and diseases using viral components |
WO2014204727A1 (en) | 2013-06-17 | 2014-12-24 | The Broad Institute Inc. | Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof |
EP3011031B1 (en) | 2013-06-17 | 2020-09-30 | The Broad Institute Inc. | Delivery and use of the crispr-cas systems, vectors and compositions for hepatic targeting and therapy |
EP3011029B1 (en) | 2013-06-17 | 2019-12-11 | The Broad Institute, Inc. | Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation |
CN105492611A (en) | 2013-06-17 | 2016-04-13 | 布罗德研究所有限公司 | Optimized CRISPR-CAS double nickase systems, methods and compositions for sequence manipulation |
US10011850B2 (en) | 2013-06-21 | 2018-07-03 | The General Hospital Corporation | Using RNA-guided FokI Nucleases (RFNs) to increase specificity for RNA-Guided Genome Editing |
US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
EP3038661B1 (en) | 2013-08-29 | 2023-12-27 | Temple University Of The Commonwealth System Of Higher Education | Methods and compositions for rna-guided treatment of hiv infection |
US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
US9340800B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | Extended DNA-sensing GRNAS |
US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
US9834791B2 (en) | 2013-11-07 | 2017-12-05 | Editas Medicine, Inc. | CRISPR-related methods and compositions with governing gRNAS |
CN105980568B (en) | 2013-12-11 | 2019-12-03 | 瑞泽恩制药公司 | Method and composition for targeting modification genome |
WO2015089351A1 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders |
EP3080271B1 (en) | 2013-12-12 | 2020-02-12 | The Broad Institute, Inc. | Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems |
US20150166984A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting alpha-antitrypsin point mutations |
EP3079725B1 (en) | 2013-12-12 | 2019-10-16 | The Broad Institute, Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for genome editing |
KR20160089530A (en) * | 2013-12-12 | 2016-07-27 | 더 브로드 인스티튜트, 인코퍼레이티드 | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for hbv and viral diseases and disorders |
WO2015089364A1 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Crystal structure of a crispr-cas system, and uses thereof |
US10286084B2 (en) * | 2014-02-18 | 2019-05-14 | Duke University | Compositions for the inactivation of virus replication and methods of making and using the same |
JP2017518372A (en) | 2014-05-30 | 2017-07-06 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Compositions and methods for delivering treatments for latent viral infections |
EA039693B1 (en) | 2014-06-16 | 2022-02-28 | Дзе Джонс Хопкинс Юниверсити | COMPOSITIONS AND METHODS FOR THE EXPRESSION OF CRISPR GUIDE RNAs USING THE H1 PROMOTER |
AU2015298571B2 (en) | 2014-07-30 | 2020-09-03 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
WO2016061374A1 (en) | 2014-10-15 | 2016-04-21 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for generating or maintaining pluripotent cells |
BR112017010547A2 (en) | 2014-11-21 | 2018-02-27 | Regeneron Pharma | methods for producing a biallelic modification, modifying a genome within a cell, producing an f0 generation from a nonhuman animal, and identifying an insertion of a nucleic acid insert. |
EP3985115A1 (en) | 2014-12-12 | 2022-04-20 | The Broad Institute, Inc. | Protected guide rnas (pgrnas) |
MA41382A (en) * | 2015-03-20 | 2017-11-28 | Univ Temple | GENE EDITING BASED ON THE TAT-INDUCED CRISPR / ENDONUCLEASE SYSTEM |
CN104726449A (en) * | 2015-03-23 | 2015-06-24 | 国家纳米科学中心 | CRISPR-Cas9 system for preventing and/or treating HIV, as well as preparation method and application thereof |
US20160287678A1 (en) * | 2015-04-02 | 2016-10-06 | Agenovir Corporation | Gene delivery methods and compositions |
EP3294343A4 (en) | 2015-05-13 | 2018-09-26 | Seattle Children's Hospital, dba Seattle Children's Research Institute | Enhancing endonuclease based gene editing in primary cells |
WO2016196282A1 (en) * | 2015-05-29 | 2016-12-08 | Agenovir Corporation | Compositions and methods for cell targeted hpv treatment |
US10117911B2 (en) | 2015-05-29 | 2018-11-06 | Agenovir Corporation | Compositions and methods to treat herpes simplex virus infections |
EP3325620A4 (en) * | 2015-05-29 | 2019-06-26 | Agenovir Corporation | Antiviral methods and compositions |
EP3919622A1 (en) | 2015-06-01 | 2021-12-08 | Temple University - Of The Commonwealth System of Higher Education | Methods and compositions for rna-guided treatment of hiv infection |
CN104894071A (en) * | 2015-06-08 | 2015-09-09 | 东华大学 | Method for carrying out gene edition on GT1-7 cells |
CN108290933A (en) | 2015-06-18 | 2018-07-17 | 布罗德研究所有限公司 | Reduce the CRISPR enzyme mutants of undershooting-effect |
WO2016205759A1 (en) | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation |
US9926546B2 (en) | 2015-08-28 | 2018-03-27 | The General Hospital Corporation | Engineered CRISPR-Cas9 nucleases |
WO2017040348A1 (en) | 2015-08-28 | 2017-03-09 | The General Hospital Corporation | Engineered crispr-cas9 nucleases |
US9512446B1 (en) | 2015-08-28 | 2016-12-06 | The General Hospital Corporation | Engineered CRISPR-Cas9 nucleases |
CN108779447A (en) * | 2015-09-28 | 2018-11-09 | 天普大学-联邦高等教育系统 | The method and composition of RNA guiding treatments for HIV infection |
US20170096649A1 (en) * | 2015-10-02 | 2017-04-06 | Agenovir Corporation | Transgenic nuclease systems and methods |
KR20180054871A (en) * | 2015-10-08 | 2018-05-24 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | Multiplexed genome editing |
CA3001130A1 (en) * | 2015-10-16 | 2017-04-20 | Temple University - Of The Commonwealth System Of Higher Education | Methods and compositions utilizing cpf1 for rna-guided gene editing |
SG10202104041PA (en) | 2015-10-23 | 2021-06-29 | Harvard College | Nucleobase editors and uses thereof |
EP3387001A4 (en) | 2015-12-09 | 2019-08-14 | Excision Biotherapeutics, Inc. | Gene editing methods and compositions for eliminating risk of jc virus activation and pml (progressive multifocal leukoencephalopathy) during immunosuppresive therapy |
US20190032057A1 (en) * | 2016-01-25 | 2019-01-31 | Excision Biotherapeutics, Inc. | Methods and compositions for rna-guided treatment of hiv infection |
AU2017219605B2 (en) * | 2016-02-15 | 2023-04-13 | Temple University - Of The Commonwealth System Of Higher Education | Excision of retroviral nucleic acid sequences |
KR20180110144A (en) * | 2016-02-26 | 2018-10-08 | 란자테크 뉴질랜드 리미티드 | CRISPR / CAS system for C1-immobilized bacteria |
EP3219799A1 (en) | 2016-03-17 | 2017-09-20 | IMBA-Institut für Molekulare Biotechnologie GmbH | Conditional crispr sgrna expression |
US20190225956A1 (en) * | 2016-05-10 | 2019-07-25 | United States Government As Represented By The Department Of Veterans Affairs | Lentiviral delivery of crispr/cas constructs that cleave genes essential for hiv-1 infection and replication |
CN107365786A (en) * | 2016-05-12 | 2017-11-21 | 中国科学院微生物研究所 | A kind of method and its application being cloned into spacer sequences in CRISPR-Cas9 systems |
WO2017213896A1 (en) * | 2016-06-03 | 2017-12-14 | Temple University - Of The Commonwealth System Of Higher Education | Negative feedback regulation of hiv-1 by gene editing strategy |
SG11201900907YA (en) | 2016-08-03 | 2019-02-27 | Harvard College | Adenosine nucleobase editors and uses thereof |
WO2018031683A1 (en) | 2016-08-09 | 2018-02-15 | President And Fellows Of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
WO2018049372A1 (en) * | 2016-09-12 | 2018-03-15 | Excision Biotherapeutics Inc | Hiv clinical plan |
EP3526320A1 (en) | 2016-10-14 | 2019-08-21 | President and Fellows of Harvard College | Aav delivery of nucleobase editors |
WO2018070850A1 (en) * | 2016-10-14 | 2018-04-19 | 연세대학교 산학협력단 | Guide rna complementary to kras gene, and use thereof |
KR101997116B1 (en) | 2016-10-14 | 2019-07-05 | 연세대학교 산학협력단 | Guide RNA complementary to KRAS gene and use thereof |
US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
US20190071673A1 (en) * | 2017-01-18 | 2019-03-07 | Thomas Malcolm | CRISPRs WITH IMPROVED SPECIFICITY |
US20190367924A1 (en) * | 2017-02-17 | 2019-12-05 | Temple University - Of The Commonwealth System Of Higher Education | Gene editing therapy for hiv infection via dual targeting of hiv genome and ccr5 |
US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
WO2018165629A1 (en) | 2017-03-10 | 2018-09-13 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
CN106755268B (en) * | 2017-03-22 | 2020-07-17 | 中国科学院海洋研究所 | Method for in vitro screening oyster active peptide with function of improving memory |
KR20190130613A (en) | 2017-03-23 | 2019-11-22 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | Nucleobase edits comprising nucleic acid programmable DNA binding proteins |
WO2018194876A1 (en) * | 2017-04-17 | 2018-10-25 | Temple University- Of The Commonwealth System Of Higher Education | An hiv-1 eradication strategy employing nanoformulated anti-retroviral drugs and gene editing agents |
WO2018195545A2 (en) | 2017-04-21 | 2018-10-25 | The General Hospital Corporation | Variants of cpf1 (cas12a) with altered pam specificity |
US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
EP3630198A4 (en) | 2017-05-25 | 2021-04-21 | The General Hospital Corporation | Using split deaminases to limit unwanted off-target base editor deamination |
JP2020534795A (en) | 2017-07-28 | 2020-12-03 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Methods and Compositions for Evolving Base Editing Factors Using Phage-Supported Continuous Evolution (PACE) |
WO2019139645A2 (en) | 2017-08-30 | 2019-07-18 | President And Fellows Of Harvard College | High efficiency base editors comprising gam |
EP3697906A1 (en) | 2017-10-16 | 2020-08-26 | The Broad Institute, Inc. | Uses of adenosine base editors |
US11618780B2 (en) | 2017-10-20 | 2023-04-04 | City Of Hope | Composition and method for activating latent human immunodeficiency virus (HIV) |
US20220194990A1 (en) * | 2019-01-31 | 2022-06-23 | Board Of Regents Of The University Of Nebraska | Virus-like particles and methods of use thereof |
WO2020163396A1 (en) | 2019-02-04 | 2020-08-13 | The General Hospital Corporation | Adenine dna base editor variants with reduced off-target rna editing |
EP3942042A1 (en) | 2019-03-19 | 2022-01-26 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
AU2020277496A1 (en) | 2019-05-23 | 2021-12-02 | Christiana Care Gene Editing Institute, Inc. | Gene knockout of variant NRF2 for treatment of cancer |
US20200370047A1 (en) | 2019-05-23 | 2020-11-26 | Christiana Care Health Services, Inc. | Gene knockout of nrf2 for treatment of cancer |
US20230257771A1 (en) | 2020-04-20 | 2023-08-17 | Christiana Care Health Services, Inc. | Aav delivery system for lung cancer treatment |
KR20230019843A (en) | 2020-05-08 | 2023-02-09 | 더 브로드 인스티튜트, 인코퍼레이티드 | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
US20230313193A1 (en) * | 2020-07-13 | 2023-10-05 | United States Government As Represented By The Department Of Veterans Affairs | Methods and compositions for crispr/cas9 guide rna efficiency and specificity against genetically diverse hiv-1 isolates |
WO2022119919A1 (en) * | 2020-12-01 | 2022-06-09 | Howell Alexandra | Compositions and methods for cleaving viral genomes |
US20220249626A1 (en) | 2021-02-05 | 2022-08-11 | Christiana Care Health Services, Inc. | Methods of and compositions for reducing gene expression and/or activity |
WO2023091696A1 (en) | 2021-11-19 | 2023-05-25 | Christiana Care Gene Editing Institute, Inc. | Adenovirus delivery system for cancer treatment |
CA3238629A1 (en) | 2021-11-19 | 2023-05-25 | Christiana Care Gene Editing Institute, Inc. | Methods for intratumoral delivery of crispr/cas systems |
US20230279442A1 (en) | 2021-12-15 | 2023-09-07 | Versitech Limited | Engineered cas9-nucleases and method of use thereof |
WO2023154451A1 (en) | 2022-02-10 | 2023-08-17 | Christiana Care Gene Editing Institute, Inc. | Methods for lipid nanoparticle delivery of crispr/cas system |
CN114657185B (en) * | 2022-03-28 | 2023-11-10 | 福州大学 | Gold magnetic nano probe based on ordered arrangement of aptamer and application of gold magnetic nano probe in field halichondrin acid detection |
CN115762764A (en) * | 2022-11-25 | 2023-03-07 | 中山大学附属第三医院 | HIV negative cryptococcus meningitis treatment outcome prediction model and construction method thereof |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
TW247876B (en) | 1993-12-28 | 1995-05-21 | New York Blood Ct Inc | Pharmaceutical compositions for prevention or treating HIV-1 or HIV-2 infection |
WO1997037005A1 (en) * | 1996-04-02 | 1997-10-09 | Progenics Pharmaceuticals, Inc. | Method for preventing hiv-1 infection of cd4+ cells |
US6392029B1 (en) * | 1997-05-09 | 2002-05-21 | The Research Foundation Of State University Of New York | HIV chemokines |
US20040132161A1 (en) * | 1998-04-20 | 2004-07-08 | Finkel Terri H. | Methods and compositions for increasing CD4lymphocyte immune responsiveness |
US6534261B1 (en) * | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
EP1849873B1 (en) * | 1999-04-29 | 2011-10-12 | Gbp Ip, Llc | Method and means for producing high titer, safe, recombinant lentivirus vectors |
US6864085B2 (en) | 1999-12-14 | 2005-03-08 | Novartis Ag | Bovine immunodeficiency virus (BIV) based vectors |
FR2825280B1 (en) | 2001-06-01 | 2005-04-15 | Merial Sas | VACCINATION AGAINST THE FELINE IMMUNODEFICIENCY VIRUS |
US20030180756A1 (en) | 2002-03-21 | 2003-09-25 | Yang Shi | Compositions and methods for suppressing eukaryotic gene expression |
US20070175484A1 (en) | 2006-01-30 | 2007-08-02 | Staab Robert J | Condoms for beneficial agents delivery |
EP1942192A1 (en) | 2007-01-08 | 2008-07-09 | Heinrich-Pette-Institut für experimentelle Virologie und Immunologie | Use of a tailored recombinase for the treatment of retroviral infections |
CN103060378A (en) | 2011-10-24 | 2013-04-24 | 四川百利药业有限责任公司 | Preparation method of SIV (simian immunodeficiency virus) vector |
GB201122458D0 (en) * | 2011-12-30 | 2012-02-08 | Univ Wageningen | Modified cascade ribonucleoproteins and uses thereof |
IL293526A (en) | 2012-12-12 | 2022-08-01 | Harvard College | C delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications |
DK2898075T3 (en) | 2012-12-12 | 2016-06-27 | Broad Inst Inc | CONSTRUCTION AND OPTIMIZATION OF IMPROVED SYSTEMS, PROCEDURES AND ENZYME COMPOSITIONS FOR SEQUENCE MANIPULATION |
EP2931899A1 (en) | 2012-12-12 | 2015-10-21 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof |
WO2014099750A2 (en) | 2012-12-17 | 2014-06-26 | President And Fellows Of Harvard College | Rna-guided human genome engineering |
WO2014165349A1 (en) | 2013-04-04 | 2014-10-09 | Trustees Of Dartmouth College | Compositions and methods for in vivo excision of hiv-1 proviral dna |
EP3038661B1 (en) | 2013-08-29 | 2023-12-27 | Temple University Of The Commonwealth System Of Higher Education | Methods and compositions for rna-guided treatment of hiv infection |
JP2017518372A (en) * | 2014-05-30 | 2017-07-06 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Compositions and methods for delivering treatments for latent viral infections |
EP3919622A1 (en) | 2015-06-01 | 2021-12-08 | Temple University - Of The Commonwealth System of Higher Education | Methods and compositions for rna-guided treatment of hiv infection |
CN108779447A (en) | 2015-09-28 | 2018-11-09 | 天普大学-联邦高等教育系统 | The method and composition of RNA guiding treatments for HIV infection |
CA3001130A1 (en) | 2015-10-16 | 2017-04-20 | Temple University - Of The Commonwealth System Of Higher Education | Methods and compositions utilizing cpf1 for rna-guided gene editing |
EP3387001A4 (en) | 2015-12-09 | 2019-08-14 | Excision Biotherapeutics, Inc. | Gene editing methods and compositions for eliminating risk of jc virus activation and pml (progressive multifocal leukoencephalopathy) during immunosuppresive therapy |
US20190032057A1 (en) | 2016-01-25 | 2019-01-31 | Excision Biotherapeutics, Inc. | Methods and compositions for rna-guided treatment of hiv infection |
CA3011270A1 (en) | 2016-01-25 | 2018-06-14 | Temple University Of The Commonwealth System Of Higher Education | Rna guided eradication of human jc virus and other polyomaviruses |
AU2017219605B2 (en) | 2016-02-15 | 2023-04-13 | Temple University - Of The Commonwealth System Of Higher Education | Excision of retroviral nucleic acid sequences |
US20190093091A1 (en) | 2016-04-06 | 2019-03-28 | Temple University - Of The Commonwealth System Of Higher Education | Compositions for eradicating flavivirus infections in subjects |
US20190093092A1 (en) | 2016-05-05 | 2019-03-28 | Temple University - Of The Commonwealth System Of Higher Education | Rna guided eradication of varicella zoster virus |
WO2017201704A1 (en) | 2016-05-26 | 2017-11-30 | Nokia Technologies Oy | Codeword adaptation for non-orthogonal coded access |
US20190256844A1 (en) | 2016-06-07 | 2019-08-22 | Temple University - Of The Commonwealth System Of Higher Education | Rna guided compositions for preventing and treating hepatitis b virus infections |
US20190085326A1 (en) | 2016-09-14 | 2019-03-21 | Temple University - Of The Commonwealth System Of Higher Education | Negative feedback regulation of HIV-1 by gene editing strategy |
US20190365862A1 (en) | 2016-10-12 | 2019-12-05 | Temple University - Of The Commonwealth System Of Higher Education | Combination therapies for eradicating flavivirus infections in subjects |
AU2018213952A1 (en) | 2017-01-26 | 2019-08-29 | Excision Biotherapeutics, Inc. | Lentivirus and non-integrating lentivirus as viral vector to deliver CRISPR therapeutic |
US20190367924A1 (en) | 2017-02-17 | 2019-12-05 | Temple University - Of The Commonwealth System Of Higher Education | Gene editing therapy for hiv infection via dual targeting of hiv genome and ccr5 |
WO2018194876A1 (en) | 2017-04-17 | 2018-10-25 | Temple University- Of The Commonwealth System Of Higher Education | An hiv-1 eradication strategy employing nanoformulated anti-retroviral drugs and gene editing agents |
US20210060138A1 (en) | 2019-03-06 | 2021-03-04 | Temple University - Of The Commonwealth System Of Higher Education | CRISPR and LASER ART Eliminates HIV |
-
2014
- 2014-08-29 EP EP14839655.9A patent/EP3038661B1/en active Active
- 2014-08-29 US US14/838,057 patent/US9925248B2/en active Active
- 2014-08-29 EA EA201600226A patent/EA037850B1/en unknown
- 2014-08-29 CA CA2922428A patent/CA2922428A1/en active Pending
- 2014-08-29 KR KR1020237002157A patent/KR20230017364A/en not_active Application Discontinuation
- 2014-08-29 CN CN201480059153.1A patent/CN106102781A/en active Pending
- 2014-08-29 JP JP2016537900A patent/JP7118588B2/en active Active
- 2014-08-29 SG SG10201801658XA patent/SG10201801658XA/en unknown
- 2014-08-29 WO PCT/US2014/053441 patent/WO2015031775A1/en active Application Filing
- 2014-08-29 BR BR112016004091A patent/BR112016004091A2/en not_active Application Discontinuation
- 2014-08-29 AU AU2014312123A patent/AU2014312123A1/en not_active Abandoned
- 2014-08-29 KR KR1020167008253A patent/KR20160060659A/en not_active IP Right Cessation
- 2014-08-29 MX MX2016002586A patent/MX2016002586A/en unknown
- 2014-08-29 SG SG11201601313TA patent/SG11201601313TA/en unknown
-
2016
- 2016-02-22 IL IL244220A patent/IL244220B/en active IP Right Grant
- 2016-02-25 CL CL2016000424A patent/CL2016000424A1/en unknown
- 2016-02-26 ZA ZA2016/01344A patent/ZA201601344B/en unknown
- 2016-05-06 US US15/148,261 patent/US9981020B2/en active Active
-
2018
- 2018-01-25 US US15/879,877 patent/US20180169193A1/en not_active Abandoned
- 2018-01-29 US US15/882,228 patent/US20180236043A1/en not_active Abandoned
- 2018-01-29 US US15/882,197 patent/US20180236041A1/en not_active Abandoned
- 2018-01-29 US US15/882,207 patent/US11285193B2/en active Active
- 2018-01-31 US US15/884,428 patent/US20180169195A1/en not_active Abandoned
- 2018-01-31 US US15/884,427 patent/US11298411B2/en active Active
- 2018-02-01 US US15/885,942 patent/US20180236046A1/en not_active Abandoned
- 2018-02-01 US US15/885,936 patent/US20180236044A1/en not_active Abandoned
- 2018-02-01 US US15/885,940 patent/US20180236045A1/en not_active Abandoned
- 2018-02-22 US US15/902,263 patent/US20180200343A1/en not_active Abandoned
- 2018-02-26 US US15/904,730 patent/US20180228874A1/en not_active Abandoned
- 2018-03-12 US US15/918,107 patent/US20180303915A1/en not_active Abandoned
- 2018-03-15 US US15/921,731 patent/US20180207243A1/en not_active Abandoned
- 2018-03-29 US US15/939,710 patent/US20180214521A1/en not_active Abandoned
- 2018-04-02 US US15/942,773 patent/US20180221458A1/en not_active Abandoned
- 2018-04-11 US US15/950,236 patent/US20180228876A1/en not_active Abandoned
- 2018-04-11 US US15/950,227 patent/US20180228875A1/en not_active Abandoned
-
2020
- 2020-04-24 JP JP2020077848A patent/JP2020188757A/en active Pending
- 2020-05-14 US US16/874,295 patent/US11291710B2/en active Active
- 2020-10-13 US US17/068,999 patent/US20210252114A1/en not_active Abandoned
- 2020-11-02 AU AU2020264257A patent/AU2020264257B2/en active Active
-
2021
- 2021-05-24 US US17/329,137 patent/US20220313795A1/en not_active Abandoned
-
2022
- 2022-06-03 US US17/832,457 patent/US20230181698A1/en active Pending
-
2023
- 2023-03-06 JP JP2023034137A patent/JP2023071897A/en active Pending
- 2023-04-11 US US18/298,913 patent/US20240139294A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201601344B (en) | Methods and compositions for rna-guided treatment of hiv infection | |
HK1253882A1 (en) | Methods and compositions for rna-guided treatment of hiv infection | |
EP3356521A4 (en) | Methods and compositions for rna-guided treatment of hiv infection | |
HK1220935A1 (en) | Method and pharmaceutical compositions for the treatment of hepatitis b virus infection | |
HK1222398A1 (en) | Compositions and methods for the treatment of burkholderia infections | |
EP2736528A4 (en) | Compositions and methods for the treatment of hiv | |
HK1210022A1 (en) | Methods for the treatment of hepatitis b and hepatitis d infections | |
HK1224210A1 (en) | Methods and compositions for treatment of fibrosis | |
HRP20181582T1 (en) | Hiv treatment formulation of atazanavir and cobicistat | |
HK1220374A1 (en) | Compositions and methods for the treatment of carboxyhemoglobinemia | |
EP2969006A4 (en) | Compositions and methods for treating an immunodeficiency virus infection | |
EP2931040A4 (en) | Methods and compositions of treating hiv infection | |
EP2968127A4 (en) | Low-glycerin formulations for hiv treatment and prevention | |
AU2013902004A0 (en) | Compositions for Therapy and Methods of Treatment |